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Until now, it has usually been considered that the best way to diagnose and appropriately treat bacterial infection was to identify the bacteria(s) responsible for the infection. This statement is accepted without debate for nearly all infections, whether they are severe (such as meningitis) or not (such as urinary tract infection). The only question is about the delay for obtaining results with the necessity, in some cases, of initiating urgent empirical antibiotic treatment. Curiously, an endless debate exists with the best technique or procedure for dignosing ventilator-associated pneumonia (VAP): clinical evaluation alone, microbiological confirmation with discussion on a lot of different diagnostic techniques or procedures; recently biomarkers have been proposed and tested \[[@B1]-[@B4]\]. VAP is difficult to diagnose in the critically ill patient because of the presence of underlying cardiopulmonary disorders (for example, atelectasis, acute respiratory distress syndrome, congestive heart failure, pulmonary contusion, and pulmonary hemorrhage), the nonspecific radiographic and clinical signs associated with this infection, and the rapid invasion of the normally sterile lower respiratory tract by microorganisms in all patients with an endotracheal tube, requiring that colonization be differentiated from true infection \[[@B2]\]. Actually, there is little information about actual clinical practice; individual studies indicate that practice often differs from recommendations in the literature \[[@B5]\]. In contrast, recommended design features of future clinical trials of antimicrobial agents for VAP - elaborated by the Infectious Disease Society of America, the American Thoracic Society, the Society of Critical Care Medicine, and the American College of Chest Physicians - stress the requirement of appropriate microbiological confirmation of infection by deep lower respiratory tract culture for inclusion in the intention-to-treat popula-tion of such trials \[[@B6]\].

These difficulties for diagnosing VAP and identifying responsible pathogen(s) lead to potential over- or under-prescription of antibiotics and misguided treatment. The strong associations between delayed diagnosis and subsequent delayed initiation of treatment or between inappropriate initial antibiotic therapy and worse outcome are well documented \[[@B7]\]. On the other hand, a recent observational study conducted in 303 patients at risk for multidrug-resistant pneumonia suggests that guideline-compliant antibiotic treatment was associated with increased mortality in comparison with nonguideline-compliant treatment \[[@B8]\].

The major potential advantage of biomarkers is not to diagnose VAP by itself but to po-tentially improve the rapidity and performance of current diagnostic procedures. The rationale is to identify and, if necessary, to dose specific markers of alveolar infection (not of bron-chial colonization): either endogenous mediators released locally by alveolar macrophages activated by microbial products or direct products of parenchymal destruction \[[@B9]\]. A number of biomarkers - including soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) \[[@B10]\], procalcitonin (PCT) \[[@B11]\], copeptin \[[@B12]\], C-reactive protein (CRP) \[[@B13]\], interleukin-1-beta, granulocyte colony-stimulating factor, macrophage inflammatory protein-1-alpha \[[@B14]\], plasminogen activation inhibitor-1 \[[@B15]\], surfactant protein D, receptor of advanced glycation end-products \[[@B16]\], midregional proatrial natriuretic peptide \[[@B17]\], and endotoxin \[[@B18]\] or elastin \[[@B19]\] fibers - have been tested recently for use in determining the diagnosis and prognosis for patients with suspected or confirmed VAP. Globally, the results of studies evaluating the value of biomarkers in diagnosing VAP are contradictory. Initially, biomarkers - particularly CRP, PCT, and sTREM-1 - were considered to be promising markers for improving diagnostic strategies of VAP. Today, the results of recent studies suggest that the measurement of biomarkers in bronchoalveolar lavage (BAL) fluid appears to have minimal diagnostic value for VAP \[[@B13],[@B20]\].

The article by Vanspauwen and colleagues \[[@B1]\] in the previous issue of *Critical Care*adds new data to the search for a biomarker for VAP. The investigators evaluated a low-molecular-weight protein secreted in the alveoli, the Clara cell protein 10 (CC-10), which has a possible anti-inflammatory role in humans \[[@B1]\]. Bronchoscopy with BAL was performed in 196 patients who were treated with mechanical ventilation for more than 48 hours and who had clinical suspicion of VAP. The authors found, in the microbiologically confirmed VAP group, a median CC-10 concentration that was significantly higher than in the non-VAP group (3,019, range 282 to 65,546 versus 2,054, range 62 to 30,240 ng/mL; *P*= 0.03), but such CC-10 levels are not discriminative for diagnosing VAP. No difference between patients with corticosteroids or antibiotic therapy and those without or between patients with Gram-positive and those with Gram-negative bacteria as responsible pathogens was observed.

In this well-conducted study, some strengths and weaknesses are worth mentioning. First, to evaluate new diagnostic techniques, a reference standard is required. For VAP, because histological confirmation is not a practical reference, quantitative cultures of BAL fluid are the best possible alternatives \[[@B2]\]. Second, bronchoscopy and lavage may be contraindicated in some patients and remain operator-dependent and time-consuming; in addition, high variability in the use of bronchoscopic sampling across intensive care units exists \[[@B5]\]. Third, an ideal diagnostic test for VAP would involve a highly discriminatory, easy-to-sample blood test. In fact, biomarkers potentially used in diagnosing VAP, including CC-10, are BAL-based techniques, just like quantitative cultures and direct examination of BAL fluid. Consequently, such a new technique is probably an extension of BAL fluid analysis in addition to microbiological techniques rather than a simplification of diagnostic procedures for VAP. Fourth, as usual in this type of study, the precise timing of sampling may influence the diagnosis of VAP. Results of CC-10 dosage in the group of non-VAP patients with a distinction between patients with negative cultures and those with more than 0 and less than 10^4^colony-forming units per milliliter (or less than 2% intracellular organisms) and data concerning the follow-up of such patients (particularly the occurrence of subsequent pneumonia) could give additional information about the ability of CC-10 dosage to predict VAP. Finally, this study did not include sequential CC-10 measurements, although recent data concerning PCT suggest that serial dosages may be used as a marker to monitor response and possibly to terminate antibiotic therapy \[[@B21]\]. Today, even if interest in surrogate markers (that is, BAL fluid biomarker dosage) to resolve the question of diagnosing or predicting VAP is not demonstrated, interest in the continuing story of biomarkers and VAP is certain.
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